NRIX Nurix Therapeutics, Inc.
NRIX Nurix Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $16.27 · VWAP $18.74 · +30.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CFO, Officer + 1 other sold $953.8K, Jul 30–Aug 5
Coverage
1 watchlist
NRIX Price Structure
Loading timeframes…
Peers
Every watchlist NRIX belongs to, members best 30-day change first — NRIX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Nurix reported third-quarter results in a press release dated October 12, 2026: revenue of $673.1M and EPS of $4.73, driven by the upfront payment under its Roche collaboration, with operating income of $559.5M and cash runway extended into 2029 (Markets Insider press-release page; Sci-Tech Today).
full note →Against street estimates
How NRIX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about NRIX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Oct 16
- Nurix Therapeutics Reports Third Quarter 2026 Financial ...
- Nurix Therapeutics earns $550M in Q3 2026 | NRIX Quarterly ...
- Stock quote & chart | Nurix Therapeutics, Inc.
- Nurix Therapeutics (NRIX) Q3 2026 Earnings Results & Report
- Nurix Therapeutics (NRIX) Stock Price & Overview
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NRIX research tape
59 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.